Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

103.800
-3.700-3.44%
Volume:17.01M
Turnover:1.76B
Market Cap:181.03B
PE:189.28
High:106.400
Open:104.300
Low:101.500
Close:107.500
52wk High:112.700
52wk Low:69.550
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:0.95
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.548
ROE:7.01%
ROA:2.10%
PB:7.48
PE(LYR):189.28
PS:9.88

Loading ...

Movement Alert|Innovent Biologics Rises 4.27% in Regular Trading, Eli Lilly Commercialization Deal and Mazdutide Insurance Review Progress

Market Focus
·
Jul 02

China's Innovent Biologics Gains Commercialization Rights for Eli Lilly Breast Cancer Drug

Reuters
·
Jun 30

Innovent, Lilly Team up to Commercialize Verzenios in Mainland China

Reuters
·
Jun 30

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

THOMSON REUTERS
·
Jun 30

Innovent Biologics - Lilly to Continue Manufacturing, Supply, and Development of Verzenios

THOMSON REUTERS
·
Jun 30

Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI

Dow Jones
·
Jun 29

Innovent Biologics' Diabetes Drug Passes Initial Review for Chinese Insurance List Inclusion

MT Newswires Live
·
Jun 29

Innovent Biologics' Mazdutide Passes Preliminary Review for China Medical Insurance Drug List- Official Statement

THOMSON REUTERS
·
Jun 29

Innovent Biologics Spokesperson: Only Treatment for Diabetes Can be Considered in Terms of Medical Insurance Coverage in China

THOMSON REUTERS
·
Jun 29

HK Movers | Hang Seng up More Than 2% Intraday, Led by CSPC PHARMA, INNOVENT BIO and Baidu

Tiger Newspress
·
Jun 29

Movement Alert|Innovent Biologics Rises 3.53% in Regular Trading, Partner Completes $330 Million Financing Amid Sector Rally

Market Focus
·
Jun 29

Movement Alert|Innovent Biologics Falls 3.01% in Regular Trading, Shareholder Meeting Resolutions Face High Opposition Amid Sector Weakness

Market Focus
·
Jun 25

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of Ibi324 (oln324) in Dme and Wet Amd; Studies Commencing in Second Half of 2026

THOMSON REUTERS
·
Jun 25

Innovent Biologics Files Directors List with Hong Kong Stock Exchange

Reuters
·
Jun 25

Ollin Raises $330 Million to Fund Late-stage Eye Disease Drug Trials

Reuters
·
Jun 24

Movement Alert|Innovent Biologics Rises 3.01% in Regular Trading, IBI3003 Phase III First Patient Dosing Continues to Drive Sentiment

Market Focus
·
Jun 24

JPMorgan Chase Increases Stake in Innovent Bio by Approximately 1.07 Million Shares at HK$75.40 Each

Stock News
·
Jun 23

Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies

Stock News
·
Jun 23

Movement Alert|Innovent Biologics Rises 3.32% in Regular Trading, IBI3003 Phase III First Patient Dosing Combined with Biotech Sector Rebound

Market Focus
·
Jun 23

Movement Alert|Innovent Biologics Falls 3.68% in Regular Trading, Biotechnology Sector Under Broad Selling Pressure

Market Focus
·
Jun 22